MAJURO, Marshall Islands, Oct. 11, 2026 (GLOBE NEWSWIRE) — Remittix has opened PayFi access to 1,000 invited RTX holders, moving its crypto-to-bank payment platform into a hands-on testing phase ahead of the scheduled November 24, 2026 token launch.

Invited participants can test EUR and USD routes while Remittix prepares additional currencies, assets and networks. The rollout lets users experience crypto-to-bank settlement before wider availability.

The milestone arrives as Bitcoin price prediction models extend toward $200,000 and Solana completes a major speed upgrade targeting 200-millisecond block times. Both developments reflect the scale of crypto’s next adoption cycle, but Remittix offers an earlier opportunity through a utility ecosystem approaching its first public-market launch.

Remittix Opens PayFi to 1,000 Invited Holders

Remittix PayFi is designed to remove the complexity that often separates cryptocurrency from everyday financial activity. A sender can fund an eligible transaction with supported digital assets while the intended recipient receives conventional currency through a compatible bank account.

The current testing phase supports crypto-to-fiat and fiat-to-crypto activity through EUR and USD routes. USDT and USDC are available across selected networks including Ethereum, Celo, Base and Polygon, with wider asset and currency support planned.

This model could serve freelancers, overseas suppliers, families sending remittances and crypto holders withdrawing portfolio value. Recipients do not need to manage tokens, exchanges or complicated off-ramps.

A Connected Ecosystem Strengthens the RTX Story

The Remittix ecosystem extends beyond payments. Its iOS wallet has recorded over 10,000 downloads, an Android edition is awaiting approval and a planned rebuild will connect the project’s major products.

Its trading platform, Remittix Markets, is already used by thousands of traders, offers hundreds of perpetual pairs and has processed more than $50 million in volume. Remittix Earn is approaching release with advertised yields of up to 22% APY on eligible crypto and stablecoin holdings.

Combining payments, asset management, derivatives trading and earning could give RTX multiple sources of recurring demand. A user entering the ecosystem to make a transfer could remain to trade, hold assets or access earning opportunities without moving capital between separate platforms.

Bitcoin Price Prediction Hits $200,000 as Solana Targets $300

Bitcoin recently traded near $83,000 after rebuilding liquidity and institutional demand during 2026. A $200,000 Bitcoin price prediction implies approximately 141% upside from that level and reflects an aggressive scenario driven by ETF adoption, corporate treasury demand and Bitcoin’s fixed supply.

Solana recently traded near $110, making $300 a potential 173% move. Its 200-millisecond block-time upgrade completes a series of cuts from 400 milliseconds and creates up to five block-production opportunities per second.

Bitcoin and Solana require substantial capital to deliver those returns. Remittix enters the same market from a much earlier stage, with PayFi already being tested before RTX reaches public exchanges.

The RTX Pre-Launch Window Is Narrowing

Remittix has raised more than $32 million from over 40,000 participants toward its $36 million hard cap. RTX is currently available at $0.23, while $0.46 is the announced final presale price and planned minimum exchange launch price.

With the November 24 date locked and invited users now testing PayFi, the remaining presale allocation represents the final entry period before open-market trading begins. Remittix is approaching that moment with payments, Markets, wallet adoption and Earn converging around a single token economy.

About Remittix

Remittix is developing a connected PayFi ecosystem for crypto-to-bank and bank-to-crypto transactions. Its products include international payment settlement, a mobile wallet, Remittix Markets and the forthcoming Remittix Earn service.

Website: https://remittix.io

X: https://x.com/remittix

Media Contact
Company: Remittix
Email: marketing@remittix.io

Disclaimer: This content is provided by Remittix. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be guaranteed. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.

Legal Disclaimer: This media platform provides the content of this article on an “as-is” basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/481c0c35-6504-400d-bb42-f3138d394f9a

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26, 2025 and August 28, 2026, both dates inclusive (the “Class Period”), of the important November 30, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Anavex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Anavex class action, go to https://rosenlegal.com/cases/anavex-life-sciences-corp-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 30, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Anavex lacked adequate internal controls; (2) Anavex’s understated its potential regulatory challenges as a result of misconduct by former Chief Executive Officer Christopher Missling; and (3) as a result, defendants’ statements about Anavex’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Anavex class action, go to https://rosenlegal.com/cases/anavex-life-sciences-corp-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40^th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        case@rosenlegal.com
        www.rosenlegal.com

President G. Gabrielle Starr Launches Originals Campaign

Center for Global Engagement Groundbreaking

Claremont, California, Oct. 10, 2026 (GLOBE NEWSWIRE) — Pomona College has publicly launched a $530 million comprehensive campaign to expand access to a Pomona education for exceptional students, with a ceremony that included a groundbreaking for its new Center for Global Engagement (CGE). The Originals Campaign, which has already raised 47% of its goal and will continue over the next five years, is the most ambitious fundraising effort in the College’s history. The campaign will strengthen and expand financial aid—including for students from middle-income families—and further invest in faculty and emerging areas of scholarship; strengthen health and wellness programs; and deepen connections across generations of Pomona College Sagehens. 

“The Originals Campaign is about ensuring that Pomona remains a place where remarkable students, whatever their discipline, can thrive regardless of financial circumstances, where faculty continue to redefine what a liberal arts education can be and where fresh ideas become meaningful change,” Pomona College President G. Gabrielle Starr says. “With the community’s partnership, we will strengthen everything that makes Pomona extraordinary while creating new opportunities for generations to come.” 

The campaign builds on Pomona’s longstanding commitment to college access: a record 29% of the year’s first-year class are first generation students, while 63% receive financial aid. A signature priority is the new middle-income initiative, designed to make a Pomona education more accessible and affordable for families who often earn too much to qualify for significant financial aid but still face substantial barriers to the cost of attendance. The campaign also expands support for programs such as the Technology Access Program (TAP) and Access to Course Essentials (ACE), which provide students with laptops, course materials and other academic necessities, helping ensure that every student has the resources needed to thrive from the moment they arrive on campus.

“Every generation of the Pomona community has inherited something extraordinary from the one before it—and then asked what it could make possible for those who would follow,” Vice President for Advancement Maria Watson says. “We are grateful for the 10,000 donors who have already supported the Originals Campaign, and we invite the entire Sagehen community to join in, whether through philanthropic support or through volunteering or participating in events.”

The campaign also includes a major investment in global education through Pomona’s new Center for Global Engagement, which broke ground as the campaign entered its public phase. Estimated for completion in Fall 2028, the 100,000-square-foot CGE will build students’ global competency, host programs for in-depth exploration of major issues facing today’s world, and house the living-and-learning communities for language and cultural understanding that have been a hallmark of Pomona for more than 60 years. The CGE’s academic work has already begun through pilot programs, including student-led programs, faculty-led study abroad and away opportunities and international collaborations. 

Pomona will also accelerate faculty-student research, expand global learning and invest in emerging areas of scholarship. In addition to the CGE, the campaign will advance Global Gateways, expand access to transformative experiences through the Summer Undergraduate Research Program (SURP) and the Pomona College Internship Program (PCIP), and support faculty research and development.

“A liberal arts education has never been about preparing students for a world that stands still,” Vice President and Chief Global Officer Kara Godwin says. “Pomona’s task is to equip students to act and lead in a dynamic world with agility and cultural humility by providing immersive experiences where they put classroom learning into practice.”

About Pomona College
Pomona College is widely regarded as one of the world’s leading liberal arts colleges, offering an ideal environment for intellectually curious students to pursue their academic and life goals. Pomona holds a unique role in creating opportunity in American higher education and is committed to enrolling the best students regardless of financial circumstances. To that end, Pomona College is one of a small group of colleges committed to meeting the full demonstrated financial need of all students who enroll. Established in 1887, the College is located in Claremont, Calif., about 35 miles east of Los Angeles.

Attachments

• President G. Gabrielle Starr Launches Originals Campaign
• Center for Global Engagement Groundbreaking

CONTACT: Rachael Warecki Pomona College 9096218503 rachael.warecki@pomona.edu 

Basel, 10 October 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart compared with a sham procedure that mimics intravitreal (IVT) injections in adults with uveitic macular edema (UME). Across both studies, data continue to support the potential for rapid and sustained improvements in vision and reductions in macular thickness (swelling in the back of the eye due to retinal fluid) with vamikibart treatment. The data were presented at the American Academy of Ophthalmology 2026 Annual Meeting (AAO 2026) in New Orleans, LA.¹

Additionally, the U.S. Food and Drug Administration (FDA) has accepted Roche’s Biologics License Application (BLA) for vamikibart for the treatment of UME. The filing acceptance is based on the results from the MEERKAT and SANDCAT studies. The FDA is expected to make a decision on approval by July 2027. If approved, vamikibart would be the first non-steroid targeted treatment for UME, with potential to establish a new standard of care. Regulatory submissions have also been filed and accepted in the European Union, China and Japan.

“These one-year results strengthen vamikibart’s clinical profile, confirming that initial visual and anatomical improvements are maintained over 52 weeks,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The acceptance of our application by the FDA and other regulatory bodies around the world brings us closer to offering a transformative, non-steroid therapy for people living with this sight-threatening condition.”

“Currently, UME is commonly treated with off-label therapies or ocular steroids, the latter carrying significant long-term side effects like glaucoma and cataract formation,” said Nisha Acharya, M.D., M.S., Distinguished Professor of Ophthalmology at UCSF and Director of the Uveitis and Ocular Inflammatory Disease Service. “Vamikibart is the first non-steroid targeted therapy to demonstrate meaningful and sustained visual and anatomical improvements in people with UME, offering a potential new treatment option that directly targets the inflammation driving this sight-threatening condition.”

The 16-week primary analysis results were presented at the AAO meeting in October 2025.² In both MEERKAT and SANDCAT at 52 weeks, a numerically higher proportion of vamikibart-treated patients achieved vision gains compared to sham treatment on the primary endpoint. Key secondary endpoints showed this benefit was maintained, with sustained improvements in average change from baseline in best corrected visual acuity (BCVA) and average change from baseline in central subfield thickness (CST), a key measure of macular edema. Vamikibart demonstrated durable clinical benefit with a low treatment burden: approximately two-thirds of eligible patients required no retreatment after 16 weeks, while the majority of those who did required only one additional injection. Vamikibart was well tolerated, maintaining a favourable safety profile, with a low incidence of treatment-related ocular adverse events (AEs) and intraocular inflammation (IOI) events.¹

UME is the leading cause of moderate-to-severe vision loss in individuals with uveitis, predominantly affecting working-age adults.^3,4 Approximately 20% of UME patients progress to sustained blindness within three years of diagnosis.⁵ Standard-of-care treatments, primarily high-dose or local corticosteroids, carry substantial long-term risks, including secondary cataracts and elevated intraocular pressure leading to glaucoma.^6-11 As a targeted anti-IL-6 monoclonal antibody, vamikibart is being developed to address these clinical unmet needs and deliver sustained visual preservation.^1,12

About the MEERKAT and SANDCAT studies
MEERKAT (NCT05642312) and SANDCAT (NCT05642325) are identical Phase III, global, parallel, multicentre, randomised, double-masked, sham comparator-controlled, 52-week trials of intravitreal (IVT) vamikibart in uveitic macular edema (UME). In both trials, patients were randomised and received treatment every four weeks with either 0.25 mg vamikibart, 1 mg vamikibart or sham IVT injection, for up to 16 weeks, followed by PRN treatment through week 52. The primary endpoint of both Phase III trials was the proportion of participants with a 15 letter or more improvement from baseline in best corrected visual acuity (BCVA) at week 16. Key secondary endpoints included the average change from baseline in BCVA and CST at week 16.  The safety of vamikibart was assessed through adverse events (AEs) such as treatment related ocular AEs, intraocular inflammation (IOI) and retinal occlusive vasculitis. The studies included participants with and without prior IVT treatment history and included patients with history of raised IOP and glaucoma.^2,13,14

About uveitic macular edema (UME)
UME is characterised by the buildup of fluid in the macula due to uveitis, an inflammatory eye condition.³ Although rare compared to other eye diseases, UME has a disproportionate impact on vision loss and blindness globally.^3,15-20 It is the leading cause of moderate and severe vision loss in people with uveitis, and the most frequent sight threatening complication in uveitis.^17-22 Uveitis accounts for 10% to 20% of blindness in the United States and Europe, and up to 25% of blindness in the developing world.²³ UME has a significant negative impact on people’s quality of life, including physical and mental health, social functioning, and visual function for day-to-day activities such as driving and reading.^22,24,25 Steroids, the current standard of care for UME, are associated with significant serious side effects such as increased pressure in the eye, glaucoma and cataracts, and have recognised efficacy limitations.^6-11

About vamikibart
Vamikibart is an investigational monoclonal antibody that has been specifically engineered for IVT administration.^1,2,12 It targets interleukin-6 (IL-6), a key cytokine in the inflammatory pathway in UME.^1,2,12 In the Phase I DOVETAIL study, vamikibart provided rapid vision improvements and resolution of macular edema in people with UME.¹² Vamikibart was also well tolerated, with no treatment-related serious adverse events reported.¹² Based on the promising Phase I DOVETAIL data, Roche initiated the two identical Phase III vamikibart studies MEERKAT and SANDCAT.^1,2,12 Vamikibart is being investigated in retinal diseases with recognised inflammatory pathways. Vamikibart has orphan drug designation in the United States and European Union.

About Roche in Ophthalmology
At Roche, we are on a mission to save and restore eyesight. Over 330 million people around the world are blind, or living with vision loss, creating a profound personal and socioeconomic burden. With the broadest pipeline in Ophthalmology, we continue to invest at scale to redefine what is medically possible in eye care.

Our comprehensive ophthalmology pipeline integrates diverse targets, advanced delivery systems, cell and gene therapies, and AI-augmented imaging capabilities, targeting multiple vision-threatening conditions, including retinal vascular and diabetic eye diseases, geographic atrophy, and autoimmune conditions, such as thyroid eye disease and uveitic macular edema.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Acharya N, et al. Vamikibart for Uveitic Macular Edema: Week 52 Efficacy and Safety Results From the Phase 3 MEERKAT and SANDCAT Trials. Presented at: the American Academy of Ophthalmology Annual Meeting (AAO 2026); 2026 October 10; New Orleans, Louisiana, United States.
[2] Khurana RN, et al. Efficacy and Safety of Vamikibart in Patients With Uveitic Macular Edema: First Report of Phase 3 MEERKAT/SANDCAT Trials. Presented at: the American Academy of Ophthalmology Annual Meeting (AAO 2025); 2025 October 17; Orlando, Florida, United States.
[3] Massa H, Pipis SY, Adewoyin T, Vergados A, Patra S, Panos GD. Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. Clin Ophthalmol. 2019;13:1761-1777. doi:10.2147/OPTH.S180580
[4] Jones NP, Pradeep A, John B. Certification of vision impairment in patients with uveitis attending a specialist clinic. Ocul Immunol Inflamm. 2019;27(4):540-544. doi:10.1080/09273948.2018.1441874
[5] Do BK, et al. Visual Outcomes by Age and Sex in Uveitic Macular Edema: Real-World Retina Registry Analysis. Presented at: the 44th Annual Meeting of the American Society of Retinal Specialists; 2026 July 15–18; Montréal, Canada.
[6] Rosenbaum JT, Bodaghi B, Couto C, et al. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review. Semin Arthritis Rheum. 2019;49(3):438-445. doi:10.1016/j.semarthrit.2019.06.004
[7] Leandro L, Beare N, Bhan K, et al. Systemic corticosteroid use in UK Uveitis practice: results from the ocular inflammation steroid toxicity risk (OSTRICH) study. Eye. 2021;35(12):3342-3349. doi:10.1038/s41433-020-01336-6
[8] Nguyen QD, Hatef E, Kayen B, et al. A Cross-sectional Study of the Current Treatment Patterns in Noninfectious Uveitis among Specialists in the United States. Ophthalmology. 2011;118(1):184-190. doi:10.1016/j.ophtha.2010.03.029
[9] Fini ME, Schwartz SG, Gao X, et al. Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine. Prog Retin Eye Res. 2017;56:58-83. doi:10.1016/j.preteyeres.2016.09.003
[10] Sen HN, Vitale S, Gangaputra SS, et al. Periocular Corticosteroid Injections in Uveitis: Effects and Complications. Ophthalmology. 2014;121(11):2275-2286. doi:10.1016/j.ophtha.2014.05.021
[11] Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. Clinical Therapeutics. 2017;39(11):2216-2229. doi:10.1016/j.clinthera.2017.09.011
[12] Sharma S, Lin P, Hu A, et al. Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized Clinical Trial. JAMA Ophthalmol. 2026;144(5):442-451. doi:10.1001/jamaophthalmol.2026.0610
[13] Hoffmann-La Roche. A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Vamikibart Administered Intravitreally in Patients With Uveitic Macular Edema. clinicaltrials.gov; 2025. Accessed September 17, 2026. https://clinicaltrials.gov/study/NCT05642312
[14] Hoffmann-La Roche. A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Vamikibart Administered Intravitreally in Patients With Uveitic Macular Edema. clinicaltrials.gov; 2026. Accessed September 17, 2026. https://clinicaltrials.gov/study/NCT05642325
[15] Teper SJ. Update on the Management of Uveitic Macular Edema. J Clin Med. 2021;10(18):4133. doi:10.3390/jcm10184133
[16] Fardeau C, Champion E, Massamba N, LeHoang P. Uveitic macular edema. Eye. 2016;30(10):1277-1292. doi:10.1038/eye.2016.115
[17] Smith JR, Thorne JE, Flaxel CJ, et al. Treatment of Noninfectious Uveitic Macular Edema with Periocular and Intraocular Corticosteroid Therapies: A Report by the American Academy of Ophthalmology. Ophthalmology. 2024;131(9):1107-1120. doi:10.1016/j.ophtha.2024.02.019
[18] Sood G, Patel BC. Uveitic Macular Edema. In: StatPearls. StatPearls Publishing; 2023. Accessed September 17, 2026. http://www.ncbi.nlm.nih.gov/books/NBK562158/
[19] Tomkins-Netzer O, Lightman SL, Burke AE, et al. Seven-Year Outcomes of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial and Follow-up Study Results. Ophthalmology. 2021;128(5):719-728. doi:10.1016/j.ophtha.2020.08.035
[20] Matas J, Llorenç V, Fonollosa A, et al. Systemic Regulatory T Cells and IL-6 as Prognostic Factors for Anatomical Improvement of Uveitic Macular Edema. Front Immunol. 2020;11:579005. doi:10.3389/fimmu.2020.579005
[21] Tomkins-Netzer O, Talat L, Bar A, et al. Long-Term Clinical Outcome and Causes of Vision Loss in Patients with Uveitis. Ophthalmology. 2014;121(12):2387-2392. doi:10.1016/j.ophtha.2014.07.007
[22] Tallouzi MO, Moore DJ, Bucknall N, et al. Outcomes important to patients with non-infectious posterior segment-involving uveitis: a qualitative study. BMJ Open Ophth. 2020;5(1):e000481. doi:10.1136/bmjophth-2020-000481
[23] Cunningham ET, Zierhut M. Vision Loss in Uveitis. Ocular Immunology and Inflammation. 2021;29(6):1037-1039. doi:10.1080/09273948.2021.2017152
[24] Tomkins-Netzer O, Lightman S, Drye L, et al. Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results. Ophthalmology. 2015;122(11):2351-2359. doi:10.1016/j.ophtha.2015.07.036
[25] Frick KD, Drye LT, Kempen JH, et al. Associations among Visual Acuity and Vision- and Health-Related Quality of Life among Patients in the Multicenter Uveitis Steroid Treatment Trial. Invest Ophthalmol Vis Sci. 2012;53(3):1169. doi:10.1167/iovs.11-8259

Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com

Roche Investor Relations

Investor Relations North America

Attachment

• Media Investor Release Vamikibart in UME English

D-Wave Reports Disappointing Financial Results
On August 6, 2026, D-Wave reported disappointing financial results for the second quarter of 2026 including, among other items, revenue of only $3.08 million, missing analyst expectations in the range of $4.03 million to $4.08 million. Then, on August 25, 2026, D-Wave issued a press release announcing the resignation of its CFO, effective September 2, 2026.

D-Wave’s Stock Drops Over 9%
Following the August 6, 2026, news of D-Wave’s poor financial results, the company’s stock price fell over 9%, and fell again, over 9%, on August 26, 2026.

Investors who purchased D-Wave Quantum Inc. (NASDAQ: QBTS) securities and experienced losses may have legal rights under the federal securities laws.

CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired D-Wave Quantum Inc. securities and have lost money on your investment, please provide your information here:
https://www.ktmc.com/qbts-dwave-quantum-inc-investigation?utm_campaign=hc?utm_source=Globe&utm_medium=pressrelease&utm_campaign=qbts&mktm=PR

There is no cost or obligation to speak with an attorney.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500’s Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs’ Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.

CONTACT:
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

The 2026 honorees are recognized not only for their professional achievements, but also for the knowledge, leadership, ideas, and expertise they bring to their fields. Through their work, these individuals contribute to important conversations, introduce new perspectives, support innovation, and help shape the direction of their respective industries. The High Impact Awards recognize these efforts and highlight the people behind work that creates meaningful influence in their communities and areas of expertise.

Each category recognizes five standout leaders whose work has made a notable impact throughout the year. The 2026 honorees represent a diverse range of professional backgrounds and areas of expertise, including technology, artificial intelligence, finance, human connection, relationships, innovation, and professional development.

The four categories announced are Real Estate, Tech and AI, Human Connection and Relationships, and Career and Leadership.

Top 5 Industry Leaders in Real Estate 2026

The Real Estate category recognizes professionals working across property investment, valuation, financing, development, and residential sales. This group represents individuals who apply their market knowledge and professional judgment to help clients navigate property decisions, build investment portfolios, and achieve their real estate goals. Their work reflects the importance of informed decision-making, trusted client relationships, and a long-term approach to creating value in the property industry.

The 2026 winners are:

#1 Richard Kenny, founder and managing partner of Falcon Capital Real Estate and Keystone Valuations
#2 Rebecca Norris DiNapoli, Realtor with Compass Tennessee
#3 Saen Higgins, CEO of Tax Lien Method
#4 Seatrice Foster, founder and chief investment officer of Avālia Capital Partners
#5 Brian T. Swan, a global real estate entrepreneur and investor

Top 5 Industry Leaders in Tech and AI 2026

The Tech and AI category recognizes professionals working at the intersection of technology, innovation, and emerging solutions. This group represents leaders who are contributing to the continued development of technology and artificial intelligence while applying their expertise to areas such as business, entrepreneurship, and organizational growth. Their work reflects the expanding role of technology in shaping how industries operate and how new solutions are developed.

The 2026 winners are:

#1 Muhamad Aly Rifai, Chief Psychiatrist and Internist at Blue Mountain Psychiatry
#2 Christy DiNapoli, CEO of West Village Entertainment and Technology
#3 Carl Case, Chief Technology Officer of ROI CX Solutions
#4 Renee Mustered, Founder of Vilomah
#5 Jabeen Zaidi, Founder and CEO of Spring AI

Top 5 Industry Leaders in Human Connection and Relationships 2026

The Human Connection and Relationships category highlights professionals whose work focuses on the ways people connect, communicate, build relationships, and create stronger communities. The honorees represent different approaches to personal development, relationships, leadership, and human connection, demonstrating the importance of meaningful interaction in both personal and professional environments.

The 2026 winners are:

#1 Daniela Climaco, CEO and founder of Behaviors of NYC and Behaviors of Florida
#2 Susi Mai, Co-founder of Ultramarine
#3 Tania Khazaal, Founder of the Renewal Collective
#4 Jennifer K. Hill, Founder of Jen Hill Tribe
#5 Rhonda Swan & Jules Schroeder, Co-founders of WildX Connect

Top 5 Industry Leaders in Career and Leadership 2026

The Career and Leadership category recognizes professionals whose work reflects leadership, career development, entrepreneurship, and professional growth. The honorees reflect a range of experience across entrepreneurship, business development, career growth, and leadership. Their backgrounds highlight the different ways professionals can contribute to their organizations, support others in their fields, and bring their experience to broader professional communities.

The 2026 winners are:

#1 Missy Kelly, Founder of CatTongue Grips and Born for Impact
#2 Brittany Anderson and Disha Solanki, Co-founders of AlignPS by The TrailblazeHers
#3 Berké Brown, Founder and CEO of Berké Brown International
#4 Ashley Holt, Founder of Ashley Holt Media Group and She Means Business Magazine
#5 Meghan Fialkoff, Co-Founder & CEO of Modern Day Wife and Founder & CEO of The Modern Day CompanyContinued Recognition of Leaders Across Industries

Recognizing professionals whose leadership, expertise, and contributions are making a meaningful impact across their respective industries, the High Impact Awards highlight a diverse group of 2026 honorees representing a wide range of professional backgrounds, experiences, and areas of expertise. Together, they reflect the many ways individuals are contributing to the growth, development, and ongoing conversations within their fields.

The 2026 High Impact Awards will continue to introduce leaders across a range of categories throughout the year. The excitement continues next month, with additional 2026 winners set to be announced, bringing attention to another group of professionals whose work, leadership, and ideas are contributing to meaningful developments across their respective fields. As the announcements continue, the initiative will further highlight the diverse group of leaders being recognized as part of the 2026 High Impact Awards.

About the High Impact Awards

The High Impact Awards are an initiative dedicated to recognizing professionals, entrepreneurs, and industry leaders who are creating meaningful impact through their work. By highlighting standout individuals across a range of industries and areas of expertise, the awards provide a platform for leaders whose contributions are helping shape their respective fields.

Through its annual recognition program, the High Impact Awards celebrate individuals demonstrating leadership, innovation, influence, and a commitment to making a difference. The 2026 awards recognize selected leaders across multiple categories, with five honorees chosen in each category.

In partnership with USA TODAY, the High Impact Awards bring greater visibility to professionals whose work is making a great impact and provide audiences with an opportunity to discover the people behind some of today’s notable businesses, initiatives, and ideas.

Media Contact

High Impact Awards

Email: contact@highimpactawards.com

Website: https://highimpactawards.com/

CONTACT: contact(at)highimpactawards.com

EVERETT, Wash., Oct. 09, 2026 (GLOBE NEWSWIRE) — Coastal Community Bank (the “Bank”, “Coastal”, “our”) announced its participation in Koz Development’s PNW Attainable Workforce Housing Fund, a community development investment focused on expanding high-quality, environmentally responsible housing for working individuals and families across the Pacific Northwest.

Koz Development’s PNW Attainable Workforce Housing Fund (“Fund”) was established to provide equity financing for attainable and workforce housing in growing communities throughout Washington and Oregon. The Fund focuses on well-located housing near employment centers, educational institutions, transportation, and essential services — places where working households can remain connected to the communities in which they live and work.

The Fund is designed to serve households that are often caught in the housing affordability gap: people who may earn too much to qualify for traditional housing assistance but still face significant challenges affording quality market-rate housing. By pairing disciplined multifamily development with mission-aligned capital, the Fund seeks to expand housing choice for this workforce or “missing middle” while supporting resilient local economies and employers.

In Washington, Coastal’s investment will also provide equity for Koz developments participating in Ballmer Group’s Washington Family Housing Fund, a philanthropic partnership with the Washington State Housing Finance Commission created to accelerate the production of affordable rental homes for families.

In announcing the investment, Coastal Community Bank said, “Across the Pacific Northwest, many working individuals and families are finding it increasingly difficult to live in the communities where they work. Workforce housing is essential to sustaining a healthy local economy, supporting employers, and ensuring that communities remain accessible and inclusive. This investment reflects our commitment to helping address one of the most significant challenges facing our region.”

“At Koz, we take tremendous pride in delivering housing that makes a meaningful difference in people’s lives,” said Cathy Reines, Founder and CEO of Koz Development. “Our residents are the people who keep our communities running — teachers, health care workers, public employees, service professionals, and working families. Creating high-quality, attainable homes for this missing middle is more than a development strategy; it is central to why we do this work. Partners like Coastal allow us to expand that impact.”

Coastal’s participation reflects a growing recognition that the region’s housing shortage requires multiple forms of capital working together. Investments in workforce and family housing can create long-term community value by supporting housing stability, access to employment and education, and the ability of communities to retain the people who make them function every day.

About Coastal Financial

Coastal Financial Corporation (Nasdaq: CCB) (the “Company”), is an Everett, Washington based bank holding company whose wholly owned subsidiaries are Coastal Community Bank (“Bank”) and Arlington Olympic LLC.  The $5.46 billion Bank provides service through 14 full-service branches in Snohomish, Island and King Counties, one loan production office in King County, the Internet and its mobile banking application. The Bank provides banking as a service to digital financial service providers, companies and brands that want to provide financial services to their customers through the Bank’s CCBX segment. To learn more about the Company visit www.coastalbank.com.

Contact
Chris D. Adams, Executive Chair of Coastal Financial Corporation, cadams@coastalbank.com
Eric Sprink, Chief Executive Officer, esprink@coastalbank.com
Joel G. Edwards, Chief Financial Officer, jedwards@coastalbank.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. Any statements about our management’s expectations, beliefs, plans, predictions, forecasts, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but not always, made through the use of words or phrases such as “anticipate,” “believes,” “can,” “could,” “may,” “predicts,” “potential,” “should,” “will,” “estimate,” “plans,” “projects,” “continuing,” “ongoing,” “expects,” “intends” and similar words or phrases. Any or all of the forward-looking statements in this press release may turn out to be inaccurate. The inclusion of or reference to forward-looking information in this press release should not be regarded as a representation by us or any other person that the future plans, estimates or expectations contemplated by us will be achieved. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Our actual results could differ materially from those anticipated in such forward-looking statements as a result of risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to effectively evaluate and manage counterparty risk associated with CCBX partners and the risk that the conflicts in the Middle East and/or changes in U.S. trade policies, including the imposition of tariffs and retaliatory tariffs, may adversely impact our business, financial condition, and results of operations and those other risks and uncertainties discussed under “Risk Factors” in our Annual Report on Form 10-K for the most recent period filed and in any of our subsequent filings with the Securities and Exchange Commission.

If one or more events related to these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may differ materially from what we anticipate. You are cautioned not to place undue reliance on forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update or revise any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as required by law.

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Alphabet Inc. (NASDAQ: GOOGL, GOOG) between May 19, 2026 and July 16, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 1, 2026.

SO WHAT: If you purchased Alphabet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Alphabet Inc. class action, go to https://rosenlegal.com/cases/alphabet-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 1, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) the Gemini 3.5 Pro was delivering disappointing training results; (2) as a result, the launch of Gemini 3.5 Pro would be significantly delayed; and (3) as a result of the foregoing, defendants’ positive statements about Alphabet’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Alphabet Inc. class action, go to https://rosenlegal.com/cases/alphabet-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        case@rosenlegal.com
        www.rosenlegal.com

T. Varneckas has served as a member of the Litgrid Board since 20 April 2022 and was elected Chair of the Board on 29 December 2022. He was re-elected for a second term as a member and Chair of the Board on 22 May 2024.

Effective 30 October, T. Varneckas will also step down from his positions as Head of Infrastructure Resilience at the EPSO-G Group and CEO of the Group company EPSO-G Invest.

The Litgrid Board currently consists of five members, two of whom are independent. Following T. Varneckas’s resignation, a decision will be made on the selection of a new Board member to serve until the end of the current Litgrid Board’s term of office on 30 April 2028.

For more information:
Jurga Eivaitė, Communications Project Manager

+370 613 19977 jurga.eivaite@litgrid.eu

NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) — Myriad360, a services-led global systems integrator, today announced that CRN®, a brand of The Channel Company, has named Myriad360 a 2026 Triple Crown Award winner. This elite recognition is awarded to solution providers that have been honored on three prestigious CRN lists in one year.

These lists include the Solution Provider 500, which ranks the largest IT solution providers operating in North America based on revenue; the Fast Growth 150, which spotlights the fastest-growing solution providers; and the Tech Elite 250, which recognizes companies that attained the highest-level certifications from leading technology vendors in the industry.

Making any of the three lists is a notable achievement, but being featured on all three in the same year demonstrates an exceptional level of business acumen, focus on innovation and dedication to building technical expertise.

Myriad360 earned its place among the 2026 Triple Crown winners after achieving its highest-ever ranking on the CRN Solution Provider 500, reaching No. 85 in its fourteenth consecutive year on the list; returning to the Fast Growth 150 following 81.7% revenue growth between 2023 and 2025; and earning a place on the Tech Elite 250 for the sixth time. This marks Myriad360’s fourth Triple Crown win since 2016.

Together, the three recognitions reflect Myriad360’s ability to scale while continuing to invest in the technical expertise, strategic partnerships and services clients need to navigate increasingly complex technology environments. The achievement comes during a year of significant momentum as Myriad360 expands its capabilities across AI, cloud, cybersecurity, networking, data center modernization and managed services.

“Earning CRN’s Triple Crown for the fourth time is a powerful validation of our momentum,” said Jay Miley, CEO and President of Myriad360. “It reflects our growth, technical excellence and our ability to deliver for clients at scale. I’m incredibly proud of our team and the way they continue to raise the bar.”

“Triple Crown Award winners exemplify the highest level of achievement in the IT channel,” said Jennifer Follett, Vice President, U.S. Content, Executive Editor, CRN, The Channel Company. “Through their dedication to innovation, technical expertise and exceptional customer support, these solution providers continue to raise the bar for industry excellence. We congratulate them on this well-deserved recognition and look forward to their continued success.”

Coverage of the 2026 Triple Crown Award winners is available at crn.com/triplecrown.

About Myriad360
Myriad360 is a services-led global systems integrator delivering agile, innovative technology solutions across cybersecurity, modern data center, networking, cloud, AI and managed services. Through personalized service, strategic partnerships and unbiased technical guidance, Myriad360 helps world-class organizations navigate complex technology initiatives, optimize investments and accelerate business outcomes. To learn more, visit myriad360.com.

About The Channel Company
The Channel Company (TCC) is the global leader in channel growth for the world’s top technology brands. We accelerate success across strategic channels for tech vendors, solution providers and end users with premier media brands, integrated marketing and event services, strategic consulting, and exclusive market and audience insights. TCC is a portfolio company of investment funds managed by EagleTree Capital, a New York City-based private equity firm. For more information, visit thechannelco.com.

CONTACT: PR Contacts: Angela Tuzzo MRB Public Relations for Myriad360 atuzzo@mrbpr.com Kristin DaSilva The Channel Company kdasilva@thechannelcompany.com